MDS

Every month, Valeria Santini, MD or Michael Savona, MD and one clinical expert will have a 30 min debate to dive deep into a hot topic in MDS/MPN Overlap Syndromes.

The one-of-a-kind clinical Roadmap will feature a live debate across the Atlantic, between EU and US speakers.

Valeria Santini, MD ( Chair )

Valeria Santini, MD ( Chair )

University of Florence, Italy

Valeria Santini is Associate Professor of Hematology at the University of Florence, Italy. She runs the MDS Unit- Hematology- Department of Experimental and Clinical Medicine- AOU Careggi, University of Florence and she is Chair of the Scientific Committee of the Italian MDS group FISiM. She graduated at the University of Florence and became a Consultant in Haematology. She worked for European Organisation for Research and Treatment of Cancer (EORTC) at Dr Daniel den Hoed Cancer Center/Erasmus University, Rotterdam, The Netherlands. She also undertook clinical training at the Leukemia Unit, M. D. Anderson Cancer Center, University of Texas, Houston. She is author of more than 200 peer-reviewed papers published in international journals focused on clinical and translational research in MDS
and elderly AML.

    Michael Savona, MD ( Chair )

    Michael Savona, MD ( Chair )

    Vanderbilt University, Nashville, Tennessee, USA

    Michael Savona is the Beverly and George Rawlings Director of Hematology Research, Head of Hematology, Cellular Therapy and Stem Cell Transplantation, and Professor of Medicine and Cancer Biology at Vanderbilt University School of Medicine. He is founder and leader of the MDS/MPN International Working Group and chair of ABNL MARRO, the first international cooperative trial testing new agents for MDS/MPN overlap syndromes. In the laboratory, he studies clonal hematopoiesis, the inflammatory changes that lead to the progression to chronic myeloid disorders and vascular disorders, and therapeutic vulnerabilities. His clinical focus and leadership in chronic myeloproliferative and myelodysplastic disease has led to the development of new therapies for these diseases.